Expert opinion on therapeutic patents · 2026
A patent review of GPR84 receptor antagonists (2020-present).
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mi Tianyu, Yin Jiawen, Chen Linhai, Nan Fajun
Аннотация
INTRODUCTION: GPR84 is a pro‑inflammatory, metabolite‑sensing Class A GPCR implicated in a range of inflammatory, fibrotic, metabolic, and neuropathic processes. Its inducible expression and role in amplifying innate immune responses have driven sustained interest in GPR84 antagonists as potential therapeutic agents.
AREAS COVERED: This review summarizes recent advances in GPR84 antagonist discovery, focusing on patent applications and research articles retrieved from SciFinder covering 2020 to January 2026.
EXPERT OPINION: Recent work and patent filings reflect continued diversification of GPR84 antagonist chemotypes, but the translational outlook remains constrained by biological uncertainty and limited clinical validation. With only a small number of candidatest-such as BAY‑3178275 and BGT‑004-currently in active development, further progress will require deeper mechanistic understanding and clearer definition of disease contexts in which GPR84 modulation may offer therapeutic benefit.
AREAS COVERED: This review summarizes recent advances in GPR84 antagonist discovery, focusing on patent applications and research articles retrieved from SciFinder covering 2020 to January 2026.
EXPERT OPINION: Recent work and patent filings reflect continued diversification of GPR84 antagonist chemotypes, but the translational outlook remains constrained by biological uncertainty and limited clinical validation. With only a small number of candidatest-such as BAY‑3178275 and BGT‑004-currently in active development, further progress will require deeper mechanistic understanding and clearer definition of disease contexts in which GPR84 modulation may offer therapeutic benefit.